Venous thromboembolism (VTE) is a common disease associated with high risk for recurrences, death, and late sequelae, accounting for substantial health care costs. Anticoagulant agents are the mainstay of treatment for deep vein thrombosis and pulmonary embolism. The recent availability of oral anticoagulant agents that can be administered in fixed doses, without laboratory monitoring and dose adjustment, is a landmark change in the treatment of VTE. In Phase III trials, rivaroxaban, apixaban, edoxaban (antifactor Xa agents), and dabigatran (an antithrombin agent) were noninferior and probably safer than conventional anticoagulation therapy (low-molecular-weight heparin followed by vitamin K antagonists). These favorable results were confirmed in specific patient subgroups, such as the elderly and 
conditions adversely affect quality of life and reduce productivity, causing a substantial burden to patients and to the health care system (14) (15) (16) (17) (18) (19) .
THE CONVENTIONAL TREATMENT OF VTE
Anticoagulant treatment of VTE includes 3 phases: an initial phase; a long-term or chronic phase; and an extended phase The rate of recurrent VTE during well-conducted anticoagulation is estimated to be about 2% (20) and that of major bleeding 2.2% (95% CI: 2.05 to 2.42) at 90 days (25, 26) . After anticoagulant treatment is stopped, the recurrence rate is low (about 3% per year or lower) in patients with VTE associated with major trauma or surgery, and it is particularly high in patients with cancer-associated VTE (about 10% per year) (27) (28) (29) . Patients treated for unprovoked VTE (no identifiable risk factors) have a recurrence rate of 15% in the 2 years after treatment discontinuation (30) . Although the rate of major bleeding during longterm anticoagulant treatment seems to decrease over time, the related case fatality rate remains stable and higher than the case fatality rate associated with recurrent VTE after anticoagulant treatment is stopped (26) .
Anticoagulant treatment is usually withdrawn after 3 months in patients with VTE associated with major temporary risk factors (e.g., surgery, trauma) and is continued indefinitely in the case of recurrence of VTE or in patients with cancer-associated thromboembolism. The optimal duration of anticoagulant treatment after the first unprovoked VTE remains unclear (20) . In these patients, prolonging anticoagulation for a definite time frame beyond the initial 3 months simply delays recurrences, without reducing the risk for this event once anticoagulation is withdrawn (11, 30) . After an unprovoked VTE, the nature of the initial thromboembolism (DVT or pul- Dabigatran is a prodrug with a bioavailability of approximately 6.5%; circulating esterases rapidly convert the prodrug to the active form, 80% of which is eliminated by the kidneys (32) . None of the factor Xa inhibitors is a prodrug, and all have oral bioavailability >50% (33) (34) (35) . The kidneys excrete one-third of rivaroxaban as active drug; the liver metabolizes twothirds of the drug to an inactive form, one-half of which is eliminated in the urine and one-half via the hepatobiliary route (33) . Apixaban is eliminated via the intestinal (about 75%) and renal (about 25%) routes (34) . Approximately one-half of edobaxan is eliminated via the renal route (35) . Time to peak concentration is similar for all of these agents, ranging from 1 to 4 h, with half-lives ranging from 6 to 17 h. Half-lives can be influenced by renal clearance, and this scenario is particularly true for dabigatran.
Care should be taken when using all NOACs in patients with impaired renal function (36) All the studies used recurrence and VTE-related death as the primary efficacy outcome. The rivaroxaban and edoxaban studies followed an event-driven design on the basis of efficacy outcomes. Major bleeding was the primary safety outcome in the apixaban trial, whereas the composite of major and clinically relevant nonmajor bleeding (clinically relevant bleeding) was the primary safety outcome in the remaining trials. Four trials enrolled patients with either DVT or pulmonary embolism, whereas the rivaroxaban program comprised 2 separate studies
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(1 for patients with DVT and 1 for patients with pulmonary embolism). The trials were double-blind, except for those with rivaroxaban (39, 40) . In the Hokusai trial, edoxaban was given as a 60-mg daily Table 2) . When NOACs are used in these patients, renal function should be checked at least twice a year (Table 3 In a meta-analysis, the results in patients with pulmonary embolism were evaluated independently from those in patients with DVT (46) . In patients with acute pulmonary embolism, recurrence of VTE Becattini and Agnelli
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RESULTS IN PARTICULAR PATIENTS
In all of the studies, subgroup analyses were performed on the efficacy and safety of NOACs in specific populations of patients.
ELDERLY PATIENTS. A recent analysis of the dabigatran trials showed that the efficacy of dabigatran compared with warfarin was to some extent higher in elderly patients (p ¼ 0.099 for interaction), with equal efficacy at approximately 60 years of age (38) . The difference in efficacy was not statistically significant at any age. Concerning clinically relevant bleeding, the risk reduction in favor of dabigatran was influenced by age (p ¼ 0.010 for interaction) and was greater in younger patients.
No age effect in efficacy and safety was observed in subgroup analyses in the rivaroxaban, apixaban, and edoxaban studies ( 20). Similarly, the presence of symptoms that are deemed to be due to distal DVT should lead to consideration of the patient for anticoagulant treatment. In this case, the accuracy of the diagnosis of distal DVT was indeed higher. §VTE is unsuspected or incidental if detected on results of imaging tests performed for other purposes. The need for anticoagulation for unsuspected VTE has never been assessed in clinical trials. In current clinical practice, anticoagulant treatment is given for unsuspected proximal DVT and at least segmental PE (20).
APLA ¼ antiphospholipid antibodies; other abbreviations as in Table 1 . Becattini and Agnelli A P R I L 2 6 , 2 0 1 6 : 1 9 4 1 -5 5
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P a t i e n t s w i t h e x t r e m e b o d y w e i g h t .
An analysis was performed to determine the association between body weight and clinical outcomes in patients treated with rivaroxaban compared with conventional therapy (51) . There was no association between body weight (#50 kg, >50 to <100 kg, and $100 kg) and risk of recurrent VTE for patients taking rivaroxaban or receiving conventional therapy ( Table 4) . Major bleeding was not associated with body weight for patients taking rivaroxaban, whereas in patients Becattini and Agnelli Treatment with concomitant NSAIDs/low-dose aspirin resulted in no statistically significant interactions for efficacy or safety. Table 2) . Ad hoc studies are currently ongoing with rivaroxaban (NCT02116036 and NCT02157272) and apixaban (NCT02295475) in patients with these abnormalities.
P a t i e n t s w i t h m o l e c u l a r t h r o m b o p h i l i a .

LIMITS OF THE AVAILABLE TRIALS LIMITED NUMBER OF PATIENTS WITH CANCER.
A proportion ranging between 2.5% and 9.4% of patients included in the Phase III trials with NOACs had cancer (37) (38) (39) (40) (41) (42) . This finding contrasts sharply with data from clinical practice reporting that about 20% of patients with VTE have cancer. In addition, it has been claimed that patients with cancer included in the NOAC Phase III trials were not completely representative of the full spectrum of patients with cancer. Indeed, it is possible that patients with more extensive disease were not included in the studies.
Furthermore, in these studies, the comparator was warfarin and not LMWH, which is considered the treatment of choice for cancer patients with VTE.
Thus, there are some concerns about whether the results of these studies are applicable to patients with cancer-associated VTE. A proposal regarding the management of surgery or invasive procedures while undergoing treatment with NOACs for VTE is reported in Figure 1 and in the Central Illustration.
NOACs FOR EXTENDED TREATMENT OF VTE DESIGN OF THE CLINICAL TRIALS.
In the extended treatment of VTE, clinical trials were conducted with dabigatran, rivaroxaban, and apixaban (Table 5) .
Dabigatran, rivaroxaban, and 2 doses of apixaban were compared with placebo in patients with uncertainty about the clinical benefit of continued anticoagulation (39, 86, 87) . Dabigatran was also compared with warfarin in patients with indications for extended treatment of VTE (86) . All of the trials of NOACs versus placebo were superiority studies, whereas the trial of dabigatran versus warfarin was a noninferiority study. The primary outcome was recurrent VTE and VTE-related death; the exception was the study with apixaban, which had recurrent VTE and overall mortality as the primary outcome.
The primary safety outcome in all of the studies was major bleeding. Treatment duration was 12 months in the dabigatran and apixaban studies versus placebo, and 6 or 12 months in the rivaroxaban study. In the study of dabigatran versus warfarin, treatment was given for up to 36 months. NOACs non inferior to LMWH followed by VKAs in the treatment of VTE and prevention of recurrences
NOACs associated with less bleeding* compared with LMWH followed by VKAs
VENOUS THROMBOEMBOLISM AND THE NOACs
Elderly:
Intermediate-high risk PE:
Renal failure:
Extreme body weight: In a meta-analysis of Phase III placebo-controlled studies on extended treatment, both all-cause mortality and recurrent VTE were lower with NOACs than with placebo (0.6% per year vs. Becattini and Agnelli However, when making decisions regarding extended treatment, the poor predictive value of commonly used bleeding risk scores should be taken into account.
The extension studies also open the way for shifting patients from conventional treatment to NOACs.
NOACs IN CLINICAL PRACTICE
The real-world safety profile of NOACs remains to be defined. If the efficacy to safety profile reported in Phase III trials is confirmed, the reduction in medical costs estimated in economic analyses could also be translated to the real world (89 Tables 1 and 3 .
lower than that seen in registries. Thus, caution should be used whenever a NOAC is to be given in compromised patients or in complex clinical settings.
Although the treatment is apparently easier, it requires a high level of clinical judgment to identify the patients to be treated and exclude those more likely to have complications.
Although associated with a reduced rate of bleeding complications, NOACs may still cause bleeding. To reduce these complications, emphasis
should be given to clinical history and patient edu- 
